AVI CEO ousted in shakeup; AB Science cuts IPO price range; Silence extends AZ pact;

 @FierceBiotech:  Boehringer looks to biotech for "targeted acquisitions." Story | Follow @FierceBiotech

 @JohnCFierce: Brain games don't make you smarter and probably won't ward off dementia. Report | Follow @JohnCFierce

> Drug prices jump 9.1% in biggest rise of the decade. Report

> A shakeup at AVI BioPharma has led to the abrupt departure of CEO Leslie Hudson. The board of the Bothell, WA-based biotech named J. David Boyle II, AVI's CFO, to the additional role of interim president and CEO. AVI release

> In a fresh sign of the often chilly market reception being given to biotechs these days, France's AB Science has cut the price range of its IPO and now expects to raise about $34.5 million. Story

> Silence Therapeutics is extending its RNAi drug research pact with AstraZeneca for another year. Release

> Millipore says that its proposed M&A deal with Merck is not being opposed by U.S. regulators. Merck struck a deal to buy Millipore for $7.2 billion. Report

> AstraZeneca is giving $25 million to a new charitable program which will offer grants of up to $150,000 to non-profit groups fighting cardiovascular disease. Story

And Finally... Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimer's disease: a receptor that is embedded in the membrane of neurons and other cells. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.